Retatrutide: research reference

What the investigational triple receptor agonist is, an index of the published research program, its regulatory status, and how to handle and verify it in a laboratory.

1. What retatrutide is

Retatrutide (development code LY3437943) is an investigational peptide from Eli Lilly. It is a single molecule that acts as an agonist at three receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). It is usually called a triple agonist. It is a 39-residue peptide with a C20 fatty diacid attached through a linker to a lysine side chain. The lipid binds albumin and extends the half-life to about six days in humans, which is why the clinical program administers it once weekly [1,2].

2. Receptor pharmacology

The three receptors have distinct roles in physiology, as studied in the incretin literature:

• GLP-1R. Glucose-dependent insulin secretion, slower gastric emptying, and appetite signalling in the brain.
• GIPR. The incretin effect on insulin secretion and signalling in adipose tissue.
• GCGR. Hepatic glucose output, hepatic lipid metabolism and energy expenditure.

Retatrutide was engineered with an intentionally unbalanced profile. In the discovery paper it was more potent than native GIP at GIPR and less potent than the native ligands at GLP-1R and GCGR [1]. For class context: semaglutide acts at GLP-1R only, tirzepatide at GIPR and GLP-1R, and retatrutide adds GCGR. The glucagon component is the pharmacological difference, and the reason the molecule is studied for liver fat and energy expenditure as well as glycaemia and body weight.

3. The published research program

This is an index of where the primary data are, so you can read them. It is not a summary of results.

Both phase 2 trials met their primary endpoints. The papers report the figures, the confidence intervals and the adverse event tables, and they are the source to read rather than any summary on a vendor site. Gastrointestinal adverse events were the most frequently reported in the treatment arms, as for the wider incretin class [3,4].

4. Regulatory status (at 27 September 2026)

• Not registered on the Australian Register of Therapeutic Goods. No retatrutide product is approved for supply as a medicine in Australia.
• Not approved by the FDA or the EMA at the time of writing. Phase 3 is the stage at which a sponsor seeks approval; check the sponsor's announcements for the current position.
• Australian pharmacists have not been able to compound GLP-1 receptor agonist products since 1 October 2024, when the TGA changed the compounding exemption.
• Material sold as a research chemical, including in this catalogue, is not a medicine, is not for human use and is not approved by the TGA.

5. Storage and handling

6. Reconstitution for lab work

1. Bring the vial to room temperature.
2. Swab the stopper.
3. Add bacteriostatic water (0.9% benzyl alcohol) down the side of the glass, not onto the powder.
4. Swirl gently. A lipidated peptide can take a few minutes to dissolve. Do not shake; shaking foams and can aggregate the peptide.
5. Label the vial with the compound, the concentration in mg/mL and the date.
6. Refrigerate.

The reconstitution calculator does the arithmetic. For example, 10 mg in 2 mL of bacteriostatic water is 5 mg/mL.

7. Reading a retatrutide certificate

• Purity by HPLC. The main peak area as a percentage. Catalogue batches are on the lab results page with the lab, the batch number and the figure.
• Identity by mass spectrometry. Expect a mass of about 4.7 kDa, reported either as a deconvoluted average mass or as a set of multiply charged ions.
• Related substances. Individual impurity peaks. Anything above about 1% deserves a question.
• Water content and counterion. Trifluoroacetate (TFA) is heavier than acetate and can be a larger share of the label weight. Both reduce net peptide content.
• Endotoxin. Relevant if the material is for cell culture or animal work, where endotoxin confounds results.

Janoshik reports carry a task number and a key you can enter at janoshik.com/verify to load the lab's own copy. The certificate guide covers the rest.

8. Quick answers

Is retatrutide the same as tirzepatide?

No. Tirzepatide acts at GIPR and GLP-1R. Retatrutide adds GCGR. They are different molecules from the same sponsor.

Is it approved anywhere?

Not at the time of writing. See the regulatory status section and check the sponsor's announcements.

Why do some listings say LY3437943?

That is the development code used before the international nonproprietary name was assigned.

Why does the powder take longer to dissolve than a small peptide?

The C20 lipid makes the molecule more hydrophobic. Give it time and gentle swirling.

What does "triple agonist" mean on a certificate?

Nothing you can see on a COA. HPLC and mass spectrometry tell you identity and purity. Receptor activity is a property of the correct sequence and lipidation, established in the discovery paper's assays.

9. In the catalogue

Retatrutide is listed as a research chemical with third-party lab results by batch.

10. References

1. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metabolism. 2022;34(9):1234-1247.
2. Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. The Lancet. 2022;400(10366):1869-1881.
3. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. New England Journal of Medicine. 2023;389(6):514-526.
4. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet. 2023;402(10401):529-544.
5. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30(7):2037-2048.
6. ClinicalTrials.gov. Search "retatrutide" for the TRIUMPH program listings and their current status.

Citations are given so you can read the primary sources. Nothing on this page is a claim about what the compound does in a person.